title: The evolving pathogenesis of systemic vasculitis.
abstract: The primary small vessel systemic vasculitides are disorders that target small blood vessels, inducing vessel wall inflammation and associated with development of antineutrophil cytoplasmic antibodies. Multiple organs are attacked including the lungs and kidneys. Increasing knowledge of pathogenesis suggests that the antibodies activate neutrophils inappropriately, leading to endothelial and vascular damage. Cytokines such as tumour necrosis factor (TNF) can facilitate the damage by priming neutrophils and activating endothelial cells. Understanding pathogenesis can help to rationalise existing therapies and indicate new approaches to therapy such as the use of agents that inhibit the effects of TNF.
authors.affiliation: Division of Medical Sciences, University of Birmingham, Edgbaston. C.O.S.Savage@bham.ac.uk
authors.forename: Caroline O S
authors.initials: CO
authors.lastname: Savage
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D017209:Apoptosis; D003520:Cyclophosphamide / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018375:Neutrophil Activation / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology; D015398:Signal Transduction; D014657:Vasculitis / Q000145:classification / Q000276:immunology* / Q000628:therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide